: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription

Articles published in Breast Cancer Res
Retrieve available abstracts of 317 articles:
HTML format

Single Articles

September 2025

KVIST A, Kampe A, Torngren T, Tesi B, et al
Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer.
Breast Cancer Res. 2025;27:160.
PubMed Abstract available

BOYACI C, Sun W, Hartman J, Acs B, et al
Global scoring method of Ki67 immunohistochemistry in breast cancer demonstrates improved concordance using real-world multi-institutional data.
Breast Cancer Res. 2025;27:159.
PubMed Abstract available

WU HC, Liao Y, Lai Y, Lin PH, et al
The plasma proteome and breast cancer risk.
Breast Cancer Res. 2025;27:157.
PubMed Abstract available

LI Y, Liu W, Yu Y, Wang Y, et al
Early thelarche, reproductive hormones, and MRI-based breast density: a prospective study in China.
Breast Cancer Res. 2025;27:158.
PubMed Abstract available

August 2025

TRINH L, Parks J, McDonald T, Roth A, et al
Pre-diagnostic serum metabolome and breast cancer risk: a nested case-control study.
Breast Cancer Res. 2025;27:156.
PubMed Abstract available

ZHANG F, de Bock GH, Landman GW, Zhang Q, et al
Longitudinal changes in metabolism-related metrics and breast cancer risk: a general population study.
Breast Cancer Res. 2025;27:155.
PubMed Abstract available

CHEN CH, Chen IC, Hsu CL, Lu TP, et al
Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses.
Breast Cancer Res. 2025;27:154.
PubMed Abstract available

WESTENEND PJ, Meurs C, Fernandez G, Prastawa M, et al
External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.
Breast Cancer Res. 2025;27:152.
PubMed Abstract available

HAMILTON E, Pluard T, Wang JS, Morikawa A, et al
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
Breast Cancer Res. 2025;27:151.
PubMed Abstract available

KLAHR MP, Faheem K, Raghunathan RR, Wooster M, et al
Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.
Breast Cancer Res. 2025;27:150.
PubMed Abstract available

PATEL R, Weil E, Bugamelli S, Carroll E, et al
Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.
Breast Cancer Res. 2025;27:147.
PubMed Abstract available

DANKNER M, Ouellet V, Lafon J, Ezzeddine R, et al
Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes.
Breast Cancer Res. 2025;27:149.
PubMed Abstract available

REEVES KW, Oulhote Y, Grandjean P, Nielsen F, et al
Associations of perfluoroalkyl substances (PFAS) with terminal ductal lobular unit involution of the normal breast.
Breast Cancer Res. 2025;27:148.
PubMed Abstract available

RAVANI LV, Bagheri Z, Brufsky AM, Michellon I, et al
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
Breast Cancer Res. 2025;27:146.
PubMed Abstract available

HUANG B, Zhang Y, Chen Z, Yuan Y, et al
Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination.
Breast Cancer Res. 2025;27:145.
PubMed Abstract available

PARISSENTI AM, Pritzker LB, Dahle MA, Gythfeldt HVL, et al
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.
Breast Cancer Res. 2025;27:143.
PubMed Abstract available

SLEDGE GWJ, Xiu J, Solzak JP, Ribeiro J, et al
Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.
Breast Cancer Res. 2025;27:144.
PubMed Abstract available

HAYASHI K, Hoshii T, Ning M, Matsumoto M, et al
Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K.
Breast Cancer Res. 2025;27:142.
PubMed Abstract available

LOPEZ-MIRANDA E, Perez-Garcia JM, Gion M, Ribelles N, et al
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.
Breast Cancer Res. 2025;27:141.
PubMed Abstract available

July 2025

LIU N, van der Velde JJS, Ramdjielal S, Koedoot E, et al
Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC.
Breast Cancer Res. 2025;27:140.
PubMed Abstract available

ZAFAR S, Badshah Y, Shabbir M, Mussarat U, et al
Missense variants in PRKCD: elucidating their potential association with breast cancer.
Breast Cancer Res. 2025;27:139.
PubMed Abstract available

HERNANDEZ A, Puppala A, Hedlich-Dwyer J, Mukherjee N, et al
Short-term consumption of the modified standard American diet perturbed the metabolic balance and altered DNA damage in MMTV-PyMT transgenic mice.
Breast Cancer Res. 2025;27:138.
PubMed Abstract available

LEE CH, Park SY, Lee JS, Kim DS, et al
MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.
Breast Cancer Res. 2025;27:136.
PubMed Abstract available

BOETTCHER L, Greimeier S, Borgmann K, Mughal SS, et al
Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer.
Breast Cancer Res. 2025;27:137.
PubMed Abstract available

DUAN F, Hua X, Lu W, Gui X, et al
Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.
Breast Cancer Res. 2025;27:135.
PubMed Abstract available

WHI W, Shin J, Kim JY, Ahn HK, et al
Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.
Breast Cancer Res. 2025;27:134.
PubMed Abstract available

TUOKKOLA JE, Reese LE, Wang Y, O'Connor CH, et al
Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.
Breast Cancer Res. 2025;27:132.
PubMed Abstract available

DO TTN, Block I, Burton M, Sorensen KP, et al
Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up.
Breast Cancer Res. 2025;27:133.
PubMed Abstract available

SKOURTI E, Seip K, Mensali N, Jabeen S, et al
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.
Breast Cancer Res. 2025;27:131.
PubMed Abstract available

JONG CL, Siesling S, Puts GCWM, Jager A, et al
The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study.
Breast Cancer Res. 2025;27:129.
PubMed Abstract available

HOLM JB, Skovbjerg SB, Nielsen HM, Christiansen P, et al
The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer.
Breast Cancer Res. 2025;27:130.
PubMed Abstract available

LUO Q, Zhang L, Hao Y, Xu C, et al
Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4.
Breast Cancer Res. 2025;27:128.
PubMed Abstract available

RIZVI N, Mucaki EJ, Salmini EL, Zhang M, et al
Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.
Breast Cancer Res. 2025;27:127.
PubMed Abstract available

DENNAOUI R, Radler PD, Wicker MN, Vistisen K, et al
Overexpression of TSG101 causes the development of adenosquamous mammary carcinoma.
Breast Cancer Res. 2025;27:126.
PubMed Abstract available

XIONG G, He D, Napier D, Chen J, et al
Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue.
Breast Cancer Res. 2025;27:125.
PubMed Abstract available

ZENG Y, Xu Z, Huang J, Yi Q, et al
THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer.
Breast Cancer Res. 2025;27:124.
PubMed Abstract available

HAMILTON EP, Patel MR, Borges VF, Meisel JL, et al
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
Breast Cancer Res. 2025;27:119.
PubMed Abstract available

MULDER CV, Jongbloed EM, Liefaard MC, Makrodimitris S, et al
A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.
Breast Cancer Res. 2025;27:120.
PubMed Abstract available

HUANG Z, Mo S, Li G, Tian H, et al
Prognosticating axillary lymph node metastasis in breast cancer through integrated photoacoustic imaging, ultrasound, and clinical parameters.
Breast Cancer Res. 2025;27:123.
PubMed Abstract available

POURALI G, Liu M, Sherpa SS, Hardi A, et al
Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials.
Breast Cancer Res. 2025;27:118.
PubMed Abstract available

BULLOCK E, Rozyczko A, Shabbir S, Tsoupi I, et al
Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.
Breast Cancer Res. 2025;27:121.
PubMed Abstract available

HIS M, Baggio I, Chabaud S, Tassy L, et al
Long-term weight change among breast cancer patients treated with chemotherapy: a longitudinal study over 13 years.
Breast Cancer Res. 2025;27:117.
PubMed Abstract available

CHAKI M, Benrashid M, Puri S, Sivakumar S, et al
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
Breast Cancer Res. 2025;27:122.
PubMed Abstract available

June 2025

RIBAS R, Pancholi S, Rani A, Schuster E, et al
Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Breast Cancer Res. 2025;27:116.
PubMed

LEON-FERRE RA, Dimitroff K, Yau C, Giridhar KV, et al
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
Breast Cancer Res. 2025;27:115.
PubMed Abstract available

RYU S, Kim HS, Lee S, Yoon SH, et al
Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models.
Breast Cancer Res. 2025;27:113.
PubMed Abstract available

CORRADO A, Lorito N, Anemone A, Carella A, et al
In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer.
Breast Cancer Res. 2025;27:112.
PubMed Abstract available

CAIRAT M, Olesen M, Olivier E, Pottegard A, et al
Systemic glucocorticoids and the risk of breast cancer in a large nationwide case-control study.
Breast Cancer Res. 2025;27:114.
PubMed Abstract available

CHANG AC, Balic M, Bartholow T, Bhargava R, et al
Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer.
Breast Cancer Res. 2025;27:111.
PubMed Abstract available

CHAO X, Wu Y, Cai X, He J, et al
Exploratory multi-cohort, multi-reader study on the clinical utility of a deep learning model for transforming cryosectioned to formalin-fixed, paraffin-embedded (FFPE) images in breast lesion diagnosis.
Breast Cancer Res. 2025;27:110.
PubMed Abstract available

IESATO A, Suzuka J, Otsuji K, Osako T, et al
Axillary adipose tissue-derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer.
Breast Cancer Res. 2025;27:109.
PubMed Abstract available

WILHELM A, Flynn C, Hammer E, Roessler J, et al
Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.
Breast Cancer Res. 2025;27:107.
PubMed Abstract available

GAO L, Zhang L, Liu J, Wang L, et al
Discovery and validation of cell-free DNA methylation markers for specific diagnosis, differentiation from benign tumors, and prognosis of breast cancer.
Breast Cancer Res. 2025;27:108.
PubMed Abstract available

VAN BAELEN K, Nguyen HL, Richard F, Zels G, et al
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
Breast Cancer Res. 2025;27:106.
PubMed Abstract available

ZHONG X, Deng J, Lu P, Zuo Z, et al
Wearable device for axillary lymph node screening in breast cancer based on infrared thermography and artificial intelligence.
Breast Cancer Res. 2025;27:104.
PubMed Abstract available

ODZER N, Chehayeb RJ, Schellhorn SE, Lustberg M, et al
Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States.
Breast Cancer Res. 2025;27:102.
PubMed Abstract available

DENNIS SR, Tsukioki T, Cottone G, Zhou W, et al
DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls.
Breast Cancer Res. 2025;27:103.
PubMed Abstract available

DING P, Pei S, Zhai Y, Qu Z, et al
Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.
Breast Cancer Res. 2025;27:101.
PubMed Abstract available

CHEN C, Yao H, Jie H, Liang Z, et al
SENP5 drives breast cancer progression through deSUMOYlation of CDK1.
Breast Cancer Res. 2025;27:100.
PubMed Abstract available

NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
Correction: Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
Breast Cancer Res. 2025;27:99.
PubMed

HU C, Zhang S, Duan F, Huang X, et al
Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.
Breast Cancer Res. 2025;27:96.
PubMed Abstract available

ZHONG HJ, Zhen Y, Chen S, Shi W, et al
Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.
Breast Cancer Res. 2025;27:97.
PubMed Abstract available

May 2025

LIU PH, Tsai CF, Hsu YC, Wu CY, et al
Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study.
Breast Cancer Res. 2025;27:95.
PubMed Abstract available

ROY R, Schunkert EM, Olivova P, Gilar M, et al
Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.
Breast Cancer Res. 2025;27:94.
PubMed Abstract available

XUAN W, Li W, Ke L, Shen Y, et al
Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes.
Breast Cancer Res. 2025;27:93.
PubMed Abstract available

GAO Y, Zuo L, Zheng Y, Sun K, et al
NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Breast Cancer Res. 2025;27:92.
PubMed Abstract available

SPYCHALSKI GB, Lin AA, Yang SJ, Shen H, et al
miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer.
Breast Cancer Res. 2025;27:90.
PubMed Abstract available

MUNHOZ J, Newell M, Goruk S, Ghosh S, et al
Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial.
Breast Cancer Res. 2025;27:91.
PubMed Abstract available

KIM H, Chun JW, Hwang J, Yun SG, et al
Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study.
Breast Cancer Res. 2025;27:89.
PubMed Abstract available

MAVADDAT N, Frost D, Zhao E, Barnes DR, et al
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE.
Breast Cancer Res. 2025;27:87.
PubMed Abstract available

CHEUNG AM, Wang D, Quintayo MA, Yerofeyeva Y, et al
Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping.
Breast Cancer Res. 2025;27:88.
PubMed Abstract available

HUANG Y, Cao Y, Chen H, Lan X, et al
Quantifying tumor morphological complexity based on pretreatment MRI fractal analysis for predicting pathologic complete response and survival in breast cancer: a retrospective, multicenter study.
Breast Cancer Res. 2025;27:86.
PubMed Abstract available

JEONG J, Yoo K, Lee J, Shin JH, et al
Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer.
Breast Cancer Res. 2025;27:85.
PubMed Abstract available

KIM JS, Lee JH, Yeon Y, An D, et al
Correction: Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
Breast Cancer Res. 2025;27:84.
PubMed

MOSHINA N, Gjesvik J, Hovda T, Koch HW, et al
Mammographic density by time and breast: a retrospective cohort study from BreastScreen Norway.
Breast Cancer Res. 2025;27:83.
PubMed Abstract available

DIAZ-SANTANA MV, Park J, Rogers M, O'Brien KM, et al
Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort.
Breast Cancer Res. 2025;27:82.
PubMed Abstract available

CARLSON EG, Lopez JC, Yamaguchi Y, Gibson J, et al
CD105(+) fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiation.
Breast Cancer Res. 2025;27:81.
PubMed Abstract available

VENETIS K, Cursano G, Scafetta R, Giachetti PPMB, et al
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.
Breast Cancer Res. 2025;27:79.
PubMed Abstract available

XU Z, Zhong S, Gao Y, Huo J, et al
Optimizing breast lesions diagnosis and decision-making with a deep learning fusion model integrating ultrasound and mammography: a dual-center retrospective study.
Breast Cancer Res. 2025;27:80.
PubMed Abstract available

ULANDAY KT, Topaz M, Shekelle J, Gibbons M, et al
Cancers missed, women dismissed yet persist: natural language processing of online forums.
Breast Cancer Res. 2025;27:78.
PubMed Abstract available

ROBINSON TJ, Liveringhouse CL, Wilson C, Friedman S, et al
Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.
Breast Cancer Res. 2025;27:77.
PubMed Abstract available

WU SY, Sharma S, Wu K, Tyagi A, et al
Retraction Note: Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
Breast Cancer Res. 2025;27:75.
PubMed

MA X, Zhang B, Yin X, Yang S, et al
CPT1A/HIF-1alpha positive feedback loop induced fatty acid oxidation metabolic pathway contributes to the L-ascorbic acid-driven angiogenesis in breast cancer.
Breast Cancer Res. 2025;27:74.
PubMed Abstract available

HEUMANN P, Benner A, Behrens S, Chang-Claude J, et al
Prognostic value of cancer-related fatigue at the end of radiotherapy for overall survival >/= 10 years in women with breast cancer.
Breast Cancer Res. 2025;27:76.
PubMed Abstract available

VETHENCOURT A, Trinidad EM, Dorca E, Petit A, et al
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
Breast Cancer Res. 2025;27:68.
PubMed Abstract available

MANGIOLA S, Brown R, Zhan C, Berthelet J, et al
Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.
Breast Cancer Res. 2025;27:73.
PubMed Abstract available

WANG X, Huang Y, Shi J, Cao Y, et al
Biomechanical parameters quantified by MR elastography for predicting response to neoadjuvant chemotherapy and disease-free survival in breast cancer: a prospective longitudinal study.
Breast Cancer Res. 2025;27:72.
PubMed Abstract available

PHI LTH, Cheng Y, Funakoshi Y, Bertucci F, et al
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
Breast Cancer Res. 2025;27:70.
PubMed Abstract available

WANG B, Chen X, Li H, Sun J, et al
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.
Breast Cancer Res. 2025;27:71.
PubMed Abstract available

HEYDARI S, Tajik F, Safaei S, Kamani F, et al
The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review.
Breast Cancer Res. 2025;27:69.
PubMed Abstract available

BRANTLEY KD, Jones ME, Tamimi RM, Rosner BA, et al
Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts.
Breast Cancer Res. 2025;27:67.
PubMed Abstract available

KIM SC, Kim GH, Park JH, Lee KH, et al
Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.
Breast Cancer Res. 2025;27:66.
PubMed Abstract available

DENG N, Kang W, Du J, Rong X, et al
Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein.
Breast Cancer Res. 2025;27:63.
PubMed Abstract available

COMINO-MENDEZ I, Velasco-Suelto J, Pascual J, Lopez-Lopez E, et al
Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.
Breast Cancer Res. 2025;27:65.
PubMed Abstract available

DONG M, Chen J, Lu N, Wang S, et al
Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis.
Breast Cancer Res. 2025;27:64.
PubMed Abstract available

April 2025

KONG L, Hu S, Zhao Y, Huang Y, et al
Neutrophil extracellular traps induced by neoadjuvant chemotherapy of breast cancer promotes vascular endothelial damage.
Breast Cancer Res. 2025;27:61.
PubMed Abstract available

LI X, Lin Z, Qiu C, Zhang Y, et al
Transfer learning drives automatic HER2 scoring on HE-stained WSIs for breast cancer: a multi-cohort study.
Breast Cancer Res. 2025;27:62.
PubMed Abstract available

MESA-EGUIAGARAY I, Wild SH, Williams LJ, Jin K, et al
Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland.
Breast Cancer Res. 2025;27:59.
PubMed Abstract available

DAI J, Rozenblit M, Li X, Shan NL, et al
Genomic alterations in normal breast tissues preceding breast cancer diagnosis.
Breast Cancer Res. 2025;27:60.
PubMed Abstract available

KIM JS, Lee JH, Yeon Y, An DY, et al
Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
Breast Cancer Res. 2025;27:58.
PubMed Abstract available

DU J, Shi J, Sun D, Wang Y, et al
Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin-eosin-stained slides.
Breast Cancer Res. 2025;27:57.
PubMed Abstract available

ZHAO Y, Song Y, Li X, Guo A, et al
Retraction Note: Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
Breast Cancer Res. 2025;27:56.
PubMed

SCHOEMAKER MJ, Ellington T, Nichols HB, Wright LB, et al
Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women.
Breast Cancer Res. 2025;27:55.
PubMed Abstract available

HAN J, Zhai X, Tao X, Li Y, et al
Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.
Breast Cancer Res. 2025;27:54.
PubMed Abstract available

YAGHJYAN L, Heng YJ, Sardella BR, Murthy D, et al
Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue.
Breast Cancer Res. 2025;27:53.
PubMed Abstract available

DU S, Xie W, Gao S, Zhao R, et al
Early prediction of neoadjuvant therapy response in breast cancer using MRI-based neural networks: data from the ACRIN 6698 trial and a prospective Chinese cohort.
Breast Cancer Res. 2025;27:52.
PubMed Abstract available

WANG Y, Jiang Y, Ding F, Lu J, et al
Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy.
Breast Cancer Res. 2025;27:51.
PubMed Abstract available

KAISER E, Weber R, Hirschstein M, Mazid H, et al
Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study.
Breast Cancer Res. 2025;27:50.
PubMed Abstract available

March 2025

WANG F, Li W, Han G, Xie J, et al
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.
Breast Cancer Res. 2025;27:47.
PubMed Abstract available

YUAN X, Rosen JM
Histone acetylation modulators in breast cancer.
Breast Cancer Res. 2025;27:49.
PubMed Abstract available

LIPERT BA, Siemens KN, Khan A, Airey R, et al
CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance.
Breast Cancer Res. 2025;27:48.
PubMed Abstract available

WU X, Li Y, Chen J, Chen J, et al
Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features.
Breast Cancer Res. 2025;27:27.
PubMed Abstract available

KRESOVICH JK, Reid BM, O'Brien KM, Xu Z, et al
DNA methylation-predicted plasma protein levels and breast cancer risk.
Breast Cancer Res. 2025;27:46.
PubMed Abstract available

LV H, Yue J, Zhang Q, Xu F, et al
Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China.
Breast Cancer Res. 2025;27:45.
PubMed Abstract available

FORTUNATO A, Mallo D, Cisneros L, King LM, et al
Evolutionary measures show that recurrence of DCIS is distinct from progression to breast cancer.
Breast Cancer Res. 2025;27:43.
PubMed Abstract available

BERGHOLTZ H, Norum JH, Lien TG, Skrede ML, et al
B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.
Breast Cancer Res. 2025;27:44.
PubMed Abstract available

BAEK SH, Lee MJ, Kook Y, Bae SJ, et al
Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer.
Breast Cancer Res. 2025;27:42.
PubMed Abstract available

LI M, Zhou S, Lv H, Cai M, et al
Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations.
Breast Cancer Res. 2025;27:41.
PubMed Abstract available

INGLE JN, Suman VJ, Solanki MH, Passow MR, et al
Evaluation of the androgen receptor in patients with ERalpha-positive early breast cancer treated with adjuvant tamoxifen +/- fluoxymesterone.
Breast Cancer Res. 2025;27:40.
PubMed Abstract available

DE MORAES FCA, de Castro Ribeiro CHD, Pessoa FDDL, Chaves JR, et al
Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.
Breast Cancer Res. 2025;27:39.
PubMed Abstract available

ZHANG D, Jahanfar S, Rabinowitz JB, Dower J, et al
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Breast Cancer Res. 2025;27:38.
PubMed Abstract available

HECKENBACH I, Peila R, Benz C, Weinmann S, et al
Cellular senescence predicts breast cancer risk from benign breast disease biopsy images.
Breast Cancer Res. 2025;27:37.
PubMed Abstract available

DENT R, Cortes J, Park YH, Munoz-Couselo E, et al
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.
Breast Cancer Res. 2025;27:35.
PubMed Abstract available

VIART NM, Renault AL, Eon-Marchais S, Jiao Y, et al
Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile.
Breast Cancer Res. 2025;27:36.
PubMed Abstract available

LEE J, Ham S, Kim N, Park HS, et al
Development of a deep learning-based model for guiding a dissection during robotic breast surgery.
Breast Cancer Res. 2025;27:34.
PubMed Abstract available

WARD AV, Riley D, Cosper KE, Finlay-Schultz J, et al
Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells.
Breast Cancer Res. 2025;27:32.
PubMed Abstract available

USUI T, Miyake T, Watabe T, Kato H, et al
Preclinical evaluation of (64)Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.
Breast Cancer Res. 2025;27:33.
PubMed Abstract available

WU S, Jiang B, Li Z, Tang Y, et al
Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.
Breast Cancer Res. 2025;27:31.
PubMed Abstract available

February 2025

FENG X, Shi Y, Wu M, Cui G, et al
Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model.
Breast Cancer Res. 2025;27:30.
PubMed Abstract available

SHI Q, Yang W, Ouyang Y, Liu Y, et al
Correction: CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Breast Cancer Res. 2025;27:28.
PubMed

WU X, Xia Y, Lou X, Huang K, et al
Decoding breast cancer imaging trends: the role of AI and radiomics through bibliometric insights.
Breast Cancer Res. 2025;27:29.
PubMed Abstract available

MARKS JR, Zhang D, Hardman T, Chen YY, et al
Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).
Breast Cancer Res. 2025;27:26.
PubMed Abstract available

DUIVON M, Christy F, Thomas E, Lequesne J, et al
Interaction between APOE E4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.
Breast Cancer Res. 2025;27:25.
PubMed Abstract available

SABETI S, Larson NB, Boughey JC, Stan DL, et al
Ultrasound-based quantitative microvasculature imaging for early prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Breast Cancer Res. 2025;27:24.
PubMed Abstract available

HUNTER NB, Peterson LM, Specht JM, Mankoff DA, et al
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Breast Cancer Res. 2025;27:23.
PubMed Abstract available

SCHMIDT G, Gluz O, Christgen M, Reinisch M, et al
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
Breast Cancer Res. 2025;27:22.
PubMed Abstract available

ZHANG L, Liu Y, Yang C, Ma J, et al
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study.
Breast Cancer Res. 2025;27:21.
PubMed Abstract available

YANG JS, Cao JM, Sun R, Zhou XJ, et al
SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.
Breast Cancer Res. 2025;27:20.
PubMed Abstract available

LOPEZ M, Spehner L, Andre F, Viot J, et al
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
Breast Cancer Res. 2025;27:19.
PubMed Abstract available

WHITMARSH T, Cope W, Carmona-Bozo J, Manavaki R, et al
Quantifying the tumour vasculature environment from CD-31 immunohistochemistry images of breast cancer using deep learning based semantic segmentation.
Breast Cancer Res. 2025;27:17.
PubMed Abstract available

GETZ KR, Jeon MS, Liu L, Liu L, et al
Metabolites and lipid species mediate the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women.
Breast Cancer Res. 2025;27:18.
PubMed Abstract available

HENRICKS J, Haddad T, Ahmed O, Schoenhals J, et al
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer.
Breast Cancer Res. 2025;27:16.
PubMed Abstract available

January 2025

SHI Q, Yang W, Ouyang Y, Liu Y, et al
CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Breast Cancer Res. 2025;27:15.
PubMed Abstract available

HABERLE L, Erber R, Gass P, Hein A, et al
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
Breast Cancer Res. 2025;27:13.
PubMed Abstract available

EHLERS FAI, Blise KE, Betts CB, Sivagnanam S, et al
Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.
Breast Cancer Res. 2025;27:14.
PubMed Abstract available

DEMICHELE A, Dueck AC, Hlauschek D, Martin M, et al
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Breast Cancer Res. 2025;27:12.
PubMed Abstract available

GABER M, Quentel A, Holmes J, Lepetit C, et al
Obesity increases DNA damage in the breast epithelium.
Breast Cancer Res. 2025;27:11.
PubMed Abstract available

ZAREAN E, Li S, Wong EM, Makalic E, et al
Tumour DNA methylation markers associated with breast cancer survival: a replication study.
Breast Cancer Res. 2025;27:9.
PubMed Abstract available

YOUNG KS, Hancock GR, Fink EC, Zigrossi A, et al
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.
Breast Cancer Res. 2025;27:10.
PubMed Abstract available

PACAUD R, Thomas S, Chaudhuri S, Lazar A, et al
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.
Breast Cancer Res. 2025;27:8.
PubMed Abstract available

AGUILAR D, Garza-Rodriguez ML, Muniz-Garza CE, Nunez FA, et al
Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.
Breast Cancer Res. 2025;27:7.
PubMed Abstract available

HU K, Wu Y, Huang Y, Zhou M, et al
Annotation-free deep learning algorithm trained on hematoxylin & eosin images predicts epithelial-to-mesenchymal transition phenotype and endocrine response in estrogen receptor-positive breast cancer.
Breast Cancer Res. 2025;27:6.
PubMed Abstract available

KIM SS, Park I, Kim J, Ka NL, et al
Secreted LGALS3BP facilitates distant metastasis of breast cancer.
Breast Cancer Res. 2025;27:4.
PubMed Abstract available

MOSTOFSKY E, Buring JE, Come SE, Tung NM, et al
Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study.
Breast Cancer Res. 2025;27:5.
PubMed Abstract available

PARK J, Chang ES, Kim JY, Chelakkot C, et al
Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Breast Cancer Res. 2025;27:3.
PubMed

FANG Z, Ren G, Ke S, Xu Q, et al
Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study.
Breast Cancer Res. 2025;27:2.
PubMed Abstract available

MAJUMDER S, Mishra S, Shinde N, Cuitino MC, et al
Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models.
Breast Cancer Res. 2025;27:1.
PubMed Abstract available

December 2024

PRZANOWSKA RK, Labban N, Przanowski P, Hawes RB, et al
Patient-derived response estimates from zero-passage organoids of luminal breast cancer.
Breast Cancer Res. 2024;26:192.
PubMed Abstract available

WANG WK, Lin HY, Lin CH, Lee HH, et al
GRK6 palmitoylation dictates triple-negative breast cancer metastasis via recruiting the beta-Arrestin 2/MAPKs/NF-kappaB signaling axis.
Breast Cancer Res. 2024;26:193.
PubMed Abstract available

LIAO CC, Long Y, Tsai ML, Lin CY, et al
G-cleave LC3B biosensor: monitoring autophagy and assessing resveratrol's synergistic impact on doxorubicin-induced apoptosis in breast cancer cells.
Breast Cancer Res. 2024;26:190.
PubMed Abstract available

LESLIE SALEWON M, Pathak R, Dooley WC, Squires RA, et al
Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare.
Breast Cancer Res. 2024;26:191.
PubMed Abstract available

YIANGOU K, Mavaddat N, Dennis J, Zanti M, et al
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.
Breast Cancer Res. 2024;26:189.
PubMed Abstract available

CHOI HL, Jeong SM, Jeon KH, Kim B, et al
Depression risk among breast cancer survivors: a nationwide cohort study in South Korea.
Breast Cancer Res. 2024;26:188.
PubMed Abstract available

GIRNIUS N, Henstridge AZ, Marks B, Yu JK, et al
Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.
Breast Cancer Res. 2024;26:187.
PubMed Abstract available

CARUSO JA, Chen-Tanyolac C, Tlsty TD
A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.
Breast Cancer Res. 2024;26:184.
PubMed Abstract available

PUPPO M, Croset M, Ceresa D, Valluru MK, et al
Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.
Breast Cancer Res. 2024;26:186.
PubMed Abstract available

KOHLER KT, Kim J, Villadsen R, Ronnov-Jessen L, et al
Oncogene activated human breast luminal progenitors contribute basally located myoepithelial cells.
Breast Cancer Res. 2024;26:183.
PubMed Abstract available

BAE SJ, Kim JH, Kim MJ, Kook Y, et al
Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study.
Breast Cancer Res. 2024;26:182.
PubMed Abstract available

MITSIADES IR, Onozato M, Iafrate AJ, Hicks D, et al
ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.
Breast Cancer Res. 2024;26:185.
PubMed Abstract available

GAO SY, Lin TC, Liu LC, Chen WL, et al
Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI.
Breast Cancer Res. 2024;26:181.
PubMed Abstract available

HAN E, Choi HY, Kwon HJ, Chung YR, et al
Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer.
Breast Cancer Res. 2024;26:180.
PubMed Abstract available

TERRY MB, English DR, Freudenheim JL, Lauby-Secretan B, et al
Alcohol cessation and breast cancer risk stratified by hormone receptor status.
Breast Cancer Res. 2024;26:179.
PubMed Abstract available

LEE DN, Li Y, Olsson LT, Hamilton AM, et al
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers.
Breast Cancer Res. 2024;26:177.
PubMed Abstract available

DEBELJAK M, Cho S, Downs BM, Considine M, et al
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
Breast Cancer Res. 2024;26:178.
PubMed Abstract available

COUNCELL KA, Polcari AM, Nordgren R, Skolarus TA, et al
Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study.
Breast Cancer Res. 2024;26:176.
PubMed Abstract available

DE LA CRUZ P, McAdams J, Morales Aquino M, Fernandez AI, et al
NF-kappaB associated markers of prognosis in early and metastatic triple negative breast cancer.
Breast Cancer Res. 2024;26:175.
PubMed Abstract available

November 2024

JUNG J, Kim NH, Park J, Lim D, et al
Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.
Breast Cancer Res. 2024;26:174.
PubMed Abstract available

LIU J, Sun W, Li N, Li H, et al
Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study.
Breast Cancer Res. 2024;26:172.
PubMed Abstract available

MORGAN E, O'Neill C, Shah R, Langselius O, et al
Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis.
Breast Cancer Res. 2024;26:171.
PubMed Abstract available

SHAHROUZI P, Azimzade Y, Brankiewicz-Kopcinska W, Bhatia S, et al
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.
Breast Cancer Res. 2024;26:170.
PubMed Abstract available

GORANSSON S, Hernandez-Varas P, Hammarstrom M, Hellgren R, et al
Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.
Breast Cancer Res. 2024;26:163.
PubMed Abstract available

CHERNOSKY NM, Tamagno I, Polak KL, Chan ER, et al
Toll-Like receptor 3-mediated interferon-beta production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.
Breast Cancer Res. 2024;26:167.
PubMed Abstract available

TEHRANIFAR P, Lee Argov EJ, Athilat S, Liao Y, et al
Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study.
Breast Cancer Res. 2024;26:166.
PubMed Abstract available

KRESOVICH JK, Guranich C, Houghton S, Qian J, et al
Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.
Breast Cancer Res. 2024;26:169.
PubMed Abstract available

FOO J, Gentile F, Massah S, Morin H, et al
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2).
Breast Cancer Res. 2024;26:168.
PubMed Abstract available

KOOK Y, Lee YJ, Chu C, Jang JS, et al
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.
Breast Cancer Res. 2024;26:164.
PubMed

GEHLING GM, Alfaqih M, Pruinelli L, Starkweather A, et al
A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.
Breast Cancer Res. 2024;26:165.
PubMed Abstract available

BI K, Chen M, Zhao Q, Yang T, et al
The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER + breast cancer but not ER- breast cancer.
Breast Cancer Res. 2024;26:161.
PubMed Abstract available

YOHANNES M, Desalegn Z, Bauer M, Stuckrath K, et al
Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients.
Breast Cancer Res. 2024;26:162.
PubMed Abstract available

CHEN H, Liu Y, Zhao J, Jia X, et al
Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study.
Breast Cancer Res. 2024;26:160.
PubMed Abstract available

MERCOEUR B, Fervers B, Coudon T, Noh H, et al
Exposure to air pollutants and breast cancer risk: mediating effects of metabolic health biomarkers in a nested case-control study within the E3N-Generations cohort.
Breast Cancer Res. 2024;26:159.
PubMed Abstract available

WADA K, Kuboyama K, Abe SK, Rahman MS, et al
Body mass index and breast cancer risk in premenopausal and postmenopausal East Asian women: a pooled analysis of 13 cohort studies.
Breast Cancer Res. 2024;26:158.
PubMed Abstract available

XIONG L, Tang X, Jiang X, Chen H, et al
Automatic segmentation-based multi-modal radiomics analysis of US and MRI for predicting disease-free survival of breast cancer: a multicenter study.
Breast Cancer Res. 2024;26:157.
PubMed Abstract available

LEE C, Yip H, Li JJX, Ng J, et al
Clinical values of nuclear morphometric analysis in fibroepithelial lesions.
Breast Cancer Res. 2024;26:156.
PubMed Abstract available

KOOK Y, Lee YJ, Chu C, Jang JS, et al
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis.
Breast Cancer Res. 2024;26:154.
PubMed Abstract available

ZUO X, Zhao X, Zhang X, Li Q, et al
PTPN20 promotes metastasis through activating NF-kappaB signaling in triple-negative breast cancer.
Breast Cancer Res. 2024;26:155.
PubMed Abstract available

MANOUCHEHRI JM, Datta J, Marcho LM, Reardon JJ, et al
The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.
Breast Cancer Res. 2024;26:153.
PubMed Abstract available

LEE YJ, Noh WC, Gwark S, Kim HA, et al
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.
Breast Cancer Res. 2024;26:152.
PubMed Abstract available

BUSUND M, Ursin G, Lund E, Chen SLF, et al
Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study.
Breast Cancer Res. 2024;26:151.
PubMed Abstract available

CHRISTENSEN MH, Vinter CA, Olesen TB, Petersen MH, et al
Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study.
Breast Cancer Res. 2024;26:150.
PubMed Abstract available

October 2024

PUTHANMADHOM NARAYANAN S, Wedn AM, Shah OS, Chen J, et al
Transcriptomic analysis identifies enrichment of cAMP/PKA/CREB signaling in invasive lobular breast cancer.
Breast Cancer Res. 2024;26:149.
PubMed Abstract available

ZHAO F, Polley E, McClellan J, Howard F, et al
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.
Breast Cancer Res. 2024;26:148.
PubMed Abstract available

JIN S, Zheng Y, Li D, Liu X, et al
Effect of genistein supplementation on microenvironment regulation of breast tumors in obese mice.
Breast Cancer Res. 2024;26:147.
PubMed Abstract available

WU W, Zhu J, Nihira NT, Togashi Y, et al
Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B.
Breast Cancer Res. 2024;26:146.
PubMed Abstract available

DWYER S, Ruth J, Seidel HE, Raz AA, et al
Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy.
Breast Cancer Res. 2024;26:143.
PubMed Abstract available

CHEN J, Kehm R, Yang W, Terry MB, et al
Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns.
Breast Cancer Res. 2024;26:145.
PubMed Abstract available

PILEHVARI A, Kimmick G, You W, Bonilla G, et al
Disparities in receipt of 1-(st) line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.
Breast Cancer Res. 2024;26:144.
PubMed Abstract available

LINDHOLM A, Abrahamsen ML, Buch-Larsen K, Marina D, et al
Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study.
Breast Cancer Res. 2024;26:142.
PubMed Abstract available

WU HC, Lai Y, Liao Y, Deyssenroth M, et al
Plasma metabolomics profiles and breast cancer risk.
Breast Cancer Res. 2024;26:141.
PubMed Abstract available

NADER-MARTA G, Singer C, Hlauschek D, DeMichele A, et al
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Breast Cancer Res. 2024;26:140.
PubMed Abstract available

September 2024

O'DRISCOLL J, Burton A, Maskarinec G, Perez-Gomez B, et al
Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study.
Breast Cancer Res. 2024;26:139.
PubMed Abstract available

SINN BV, Sychra K, Untch M, Karn T, et al
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res. 2024;26:138.
PubMed Abstract available

JIANG B, Bao L, He S, Chen X, et al
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.
Breast Cancer Res. 2024;26:137.
PubMed Abstract available

BORAKA O, Sartor H, Sturesdotter L, Hall P, et al
WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer.
Breast Cancer Res. 2024;26:136.
PubMed Abstract available

ZHANG N, Wang Q, Lu Y, Wang F, et al
The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5.
Breast Cancer Res. 2024;26:135.
PubMed Abstract available

OZANNE EM, Maves K, Tramontano AC, Lynch T, et al
Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25).
Breast Cancer Res. 2024;26:134.
PubMed Abstract available

TARANTO P, de Brito Sales D, Maluf FC, Guendelmann RAK, et al
Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy.
Breast Cancer Res. 2024;26:133.
PubMed Abstract available

OMAR M, Harrell JC, Tamimi R, Marchionni L, et al
A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
Breast Cancer Res. 2024;26:132.
PubMed Abstract available

LIEN HC, Yu HC, Yu WH, Lin SF, et al
Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma.
Breast Cancer Res. 2024;26:130.
PubMed Abstract available

PHUNG AT, Shah JR, Dong T, Reid T, et al
CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.
Breast Cancer Res. 2024;26:131.
PubMed Abstract available

ZHANG Y, Zhong F, Liu L
Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer.
Breast Cancer Res. 2024;26:129.
PubMed Abstract available

XUE X, Guo L, Guo C, Xu L, et al
Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China.
Breast Cancer Res. 2024;26:128.
PubMed Abstract available

STRAND SH, Houlahan KE, Branch V, Lynch T, et al
Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome.
Breast Cancer Res. 2024;26:127.
PubMed Abstract available

August 2024

INGEBRIKTSEN LM, Humlevik ROC, Svanoe AA, Saele AKM, et al
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.
Breast Cancer Res. 2024;26:126.
PubMed Abstract available

VAN BOCKSTAL MR, Wesseling J, Lips EH, Smidt M, et al
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
Breast Cancer Res. 2024;26:125.
PubMed Abstract available

VALIERIS R, Martins L, Defelicibus A, Bueno AP, et al
Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides.
Breast Cancer Res. 2024;26:124.
PubMed Abstract available

SHARMA A, Lovgren SK, Eriksson KL, Wang Y, et al
Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images.
Breast Cancer Res. 2024;26:123.
PubMed Abstract available

MORAGAS N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, et al
The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.
Breast Cancer Res. 2024;26:122.
PubMed Abstract available

ZHAO Y, Song Y, Li X, Guo A, et al
Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
Breast Cancer Res. 2024;26:121.
PubMed Abstract available

July 2024

LEE J, Park S, Bae SJ, Ji J, et al
Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy.
Breast Cancer Res. 2024;26:120.
PubMed Abstract available

HAO J, Jin R, Yi Y, Jiang X, et al
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer.
Breast Cancer Res. 2024;26:119.
PubMed Abstract available

KADAMKULAM SYRIAC A, Nandu NS, Clark A, Tavallai M, et al
Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes.
Breast Cancer Res. 2024;26:118.
PubMed Abstract available

HUANG Y, Chen C, Liu Y, Tan B, et al
Downregulation of tRF-Cys-GCA-029 by hyperglycemia promotes tumorigenesis and glycolysis of diabetic breast cancer through upregulating PRKCG translation.
Breast Cancer Res. 2024;26:117.
PubMed Abstract available

MBURU W, Guo C, Tian Y, Koka H, et al
Associations between quantitative measures of mammographic density and terminal ductal lobular unit involution in Chinese breast cancer patients.
Breast Cancer Res. 2024;26:116.
PubMed Abstract available

KADER T, Provenzano E, Jayawardana MW, Hendry S, et al
Stromal lymphocytes are associated with upgrade of B3 breast lesions.
Breast Cancer Res. 2024;26:115.
PubMed Abstract available

GAO H, Wei L, Indulkar S, Nguyen TTL, et al
Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.
Breast Cancer Res. 2024;26:111.
PubMed Abstract available

YANG X, Liu Q, Guo Z, Yang X, et al
Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.
Breast Cancer Res. 2024;26:112.
PubMed Abstract available

SUBRAMANYAN LV, Rasheed SAK, Wang L, Ghosh S, et al
GNA13 suppresses proliferation of ER+ breast cancer cells via ERalpha dependent upregulation of the MYC oncogene.
Breast Cancer Res. 2024;26:113.
PubMed Abstract available

XIAO D, Zhang M, Qu Y, Su X, et al
Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target.
Breast Cancer Res. 2024;26:110.
PubMed Abstract available

HENG YJ, Baker GM, Fein-Zachary VJ, Guzman-Arocho YD, et al
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.
Breast Cancer Res. 2024;26:109.
PubMed Abstract available

WANG C, Nagayach A, Patel H, Dao L, et al
Utilizing human cerebral organoids to model breast cancer brain metastasis in culture.
Breast Cancer Res. 2024;26:108.
PubMed Abstract available

June 2024

SINEVICI N, Edmonds CE, Dontchos BN, Wang G, et al
A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.
Breast Cancer Res. 2024;26:107.
PubMed Abstract available

FIFIELD BA, Vusich J, Haberfellner E, Andrechek ER, et al
Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.
Breast Cancer Res. 2024;26:106.
PubMed Abstract available

WANG D, Yang S, Lyu M, Xu L, et al
Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway.
Breast Cancer Res. 2024;26:105.
PubMed Abstract available

LU Y, Houson HA, Gallegos CA, Mascioni A, et al
Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
Breast Cancer Res. 2024;26:104.
PubMed Abstract available

FANG Y, Wang Y, Ma H, Guo Y, et al
TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription.
Breast Cancer Res. 2024;26:103.
PubMed Abstract available

HARRIS AR, Wang T, Heng YJ, Baker GM, et al
Association of early menarche with breast tumor molecular features and recurrence.
Breast Cancer Res. 2024;26:102.
PubMed Abstract available

BHIMANI J, O'Connell K, Ergas IJ, Foley M, et al
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019.
Breast Cancer Res. 2024;26:101.
PubMed Abstract available

ZHANG Y, Chen F, Balic M, Creighton CJ, et al
An essential gene signature of breast cancer metastasis reveals targetable pathways.
Breast Cancer Res. 2024;26:98.
PubMed Abstract available

LIEN HC, Lo C, Lee YH, Lin PH, et al
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
Breast Cancer Res. 2024;26:100.
PubMed Abstract available

DU J, Liu X, Sun J, Wu Q, et al
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer.
Breast Cancer Res. 2024;26:99.
PubMed Abstract available

LEON-FERRE RA, Whitaker KR, Suman VJ, Hoskin T, et al
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
Breast Cancer Res. 2024;26:97.
PubMed Abstract available

COLEMAN MF, Cotul EK, Pfeil AJ, Devericks EN, et al
Hypoxia-mediated repression of pyruvate carboxylase drives immunosuppression.
Breast Cancer Res. 2024;26:96.
PubMed Abstract available

LAINE M, Greene ME, Kurleto JD, Bozek G, et al
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
Breast Cancer Res. 2024;26:95.
PubMed Abstract available

ZHANG X, An K, Ge X, Sun Y, et al
NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation.
Breast Cancer Res. 2024;26:94.
PubMed Abstract available

DUIVON M, Lequesne J, Di Meglio A, Pradon C, et al
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
Breast Cancer Res. 2024;26:93.
PubMed Abstract available

JIN X, Yang S, Lu X, Chen X, et al
Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
Breast Cancer Res. 2024;26:92.
PubMed Abstract available

FARALDO MM, Romagnoli M, Wallon L, Dubus P, et al
Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
Breast Cancer Res. 2024;26:91.
PubMed Abstract available

MORLA-BARCELO PM, Laguna-Macarrilla D, Cordoba O, Matheu G, et al
Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.
Breast Cancer Res. 2024;26:89.
PubMed Abstract available

BOISSIN C, Wang Y, Sharma A, Weitz P, et al
Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images.
Breast Cancer Res. 2024;26:90.
PubMed Abstract available

May 2024

JOHN EM, Koo J, Phipps AI, Longacre TA, et al
Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
Breast Cancer Res. 2024;26:88.
PubMed Abstract available

GLOTZBACH A, Rohlf K, Gonscharow A, Luke S, et al
EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.
Breast Cancer Res. 2024;26:87.
PubMed Abstract available

RAGHURAM N, Temel EI, Kawamata T, Kozma KJ, et al
Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
Breast Cancer Res. 2024;26:86.
PubMed Abstract available

JONES LI, Marshall A, Geach R, Elangovan P, et al
Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using a
Breast Cancer Res. 2024;26:85.
PubMed Abstract available

KUKLINSKI D, Blum M, Subelack J, Geissler A, et al
Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival.
Breast Cancer Res. 2024;26:84.
PubMed Abstract available

JACOBS SA, Wang Y, Abraham J, Feng H, et al
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res. 2024;26:83.
PubMed

LIU C, Sun M, Arefan D, Zuley M, et al
Deep learning of mammogram images to reduce unnecessary breast biopsies: a preliminary study.
Breast Cancer Res. 2024;26:82.
PubMed Abstract available

VAN CAUWENBERGE J, Van Baelen K, Maetens M, Geukens T, et al
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
Breast Cancer Res. 2024;26:81.
PubMed Abstract available

MAO H, Jin M, Xie L, Mao N, et al
Infrared laser moxibustion for cancer-related fatigue in breast cancer survivors: a randomized controlled trial.
Breast Cancer Res. 2024;26:80.
PubMed Abstract available

NELSON A, McMullen N, Gebremeskel S, De Antueno R, et al
Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Breast Cancer Res. 2024;26:78.
PubMed Abstract available

MARIAPUN S, Ho WK, Eriksson M, Mohd Taib NA, et al
Association of area- and volumetric-mammographic density and breast cancer risk in women of Asian descent: a case control study.
Breast Cancer Res. 2024;26:79.
PubMed Abstract available

ZHANG X, Teng X, Zhang J, Lai Q, et al
Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
Breast Cancer Res. 2024;26:77.
PubMed Abstract available

RAJ-KUMAR PK, Lin X, Liu T, Sturtz LA, et al
Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
Breast Cancer Res. 2024;26:76.
PubMed Abstract available

OMILIAN AR, Cannioto R, Mendicino L, Stein L, et al
CD163(+) macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study.
Breast Cancer Res. 2024;26:75.
PubMed Abstract available

April 2024

SMITH RE, Sprague BL, Henderson LM, Kerlikowske K, et al
Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
Breast Cancer Res. 2024;26:73.
PubMed Abstract available

CHAUDHARY P, Yadav K, Lee HJ, Kang KW, et al
siRNA treatment targeting integrin alpha11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Breast Cancer Res. 2024;26:72.
PubMed Abstract available

HE L, Qin Y, Hu Q, Liu Z, et al
Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging.
Breast Cancer Res. 2024;26:71.
PubMed Abstract available

LIAO R, Chen X, Cao Q, Bai L, et al
AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
Breast Cancer Res. 2024;26:70.
PubMed Abstract available

JACOBS SA, Wang Y, Abraham J, Feng H, et al
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res. 2024;26:69.
PubMed Abstract available

PAN JW, Ragu M, Chan WQ, Hasan SN, et al
Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
Breast Cancer Res. 2024;26:67.
PubMed Abstract available

KWON MR, Chang Y, Ham SY, Cho Y, et al
Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection.
Breast Cancer Res. 2024;26:68.
PubMed Abstract available

BAE SJ, Chun JW, Lee SB, Ryu JM, et al
Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.
Breast Cancer Res. 2024;26:66.
PubMed Abstract available

Meeting Abstracts from the British Society of Breast Radiology annual scientific meeting 2023.
Breast Cancer Res. 2024;26.
PubMed

ZHANG N, Huang Y, Wang G, Xiang Y, et al
Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
Breast Cancer Res. 2024;26:64.
PubMed Abstract available

BAE SJ, Kook Y, Jang JS, Baek SH, et al
Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
Breast Cancer Res. 2024;26:65.
PubMed Abstract available

SALEMBIER R, De Haes C, Bellemans J, Demeyere K, et al
Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Breast Cancer Res. 2024;26:63.
PubMed Abstract available

ZHANG W, Song X, Jin Z, Zhang Y, et al
U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
Breast Cancer Res. 2024;26:60.
PubMed Abstract available

KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
Breast Cancer Res. 2024;26:61.
PubMed Abstract available

WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
Breast Cancer Res. 2024;26:59.
PubMed Abstract available

BASHARI MH, Fan F, Vallet S, Sattler M, et al
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Breast Cancer Res. 2024;26:58.
PubMed

March 2024

OLIPHANT MUJ, Akshinthala D, Muthuswamy SK
Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
Breast Cancer Res. 2024;26:56.
PubMed Abstract available

CHI F, Griffiths JI, Nath A, Bild AH, et al
Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
Breast Cancer Res. 2024;26:54.
PubMed Abstract available

SAFAEI S, Fadaee M, Farzam OR, Yari A, et al
Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
Breast Cancer Res. 2024;26:57.
PubMed Abstract available

WALLACE G, Kundalia R, Vallebuona E, Cao B, et al
Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Breast Cancer Res. 2024;26:55.
PubMed Abstract available

MULLOOLY M, Fan S, Pfeiffer RM, Bowles EA, et al
Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease.
Breast Cancer Res. 2024;26:52.
PubMed Abstract available

QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
Breast Cancer Res. 2024;26:53.
PubMed

HAMILTON AM, Walens A, Van Alsten SC, Olsson LT, et al
BIRC5 expression by race, age and clinical factors in breast cancer patients.
Breast Cancer Res. 2024;26:50.
PubMed Abstract available

MCCLELLAN JC, Li JL, Gao G, Huo D, et al
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
Breast Cancer Res. 2024;26:51.
PubMed Abstract available

LEE J, Lee G, Park HS, Jeong BK, et al
Factors associated with engraftment success of patient-derived xenografts of breast cancer.
Breast Cancer Res. 2024;26:49.
PubMed Abstract available

HU R, Cao Y, Wang Y, Zhao T, et al
TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via beta1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Breast Cancer Res. 2024;26:48.
PubMed Abstract available

GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
Breast Cancer Res. 2024;26:47.
PubMed Abstract available

SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Breast Cancer Res. 2024;26:46.
PubMed

PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
Breast Cancer Res. 2024;26:45.
PubMed Abstract available

JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
Breast Cancer Res. 2024;26:42.
PubMed Abstract available

CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
Breast Cancer Res. 2024;26:43.
PubMed Abstract available

BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Breast Cancer Res. 2024;26:41.
PubMed Abstract available

LI J, Liang Y, Zhou S, Chen J, et al
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
Breast Cancer Res. 2024;26:44.
PubMed Abstract available

ZHAO L, Xing Y, Liu C, Ma S, et al
Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
Breast Cancer Res. 2024;26:40.
PubMed Abstract available

CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
Breast Cancer Res. 2024;26:38.
PubMed Abstract available

HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
Breast Cancer Res. 2024;26:39.
PubMed Abstract available

JIANG X, Wang Y, Guo L, Wang Y, et al
The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
Breast Cancer Res. 2024;26:37.
PubMed Abstract available

RODON J, Demanse D, Rugo HS, Burris HA, et al
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res. 2024;26:36.
PubMed Abstract available

SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Breast Cancer Res. 2024;26:35.
PubMed Abstract available

February 2024

SONG T, Zhang H, Zhao Q, Hu Z, et al
Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
Breast Cancer Res. 2024;26:33.
PubMed Abstract available

EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
Breast Cancer Res. 2024;26:34.
PubMed Abstract available

SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Breast Cancer Res. 2024;26:32.
PubMed Abstract available

JUNG M, Song SG, Cho SI, Shin S, et al
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Breast Cancer Res. 2024;26:31.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.